NAVLIN Daily by EVERSANA looks back at a year of rapid and often unpredictable global pricing and policy shifts that reshaped launch and access strategies worldwide.
Throughout 2025, the NAVLIN Daily team supported the life sciences community with timely insights, policy and MFN tracking, and enhanced digital tools designed to help navigate an increasingly complex environment.
NAVLIN Daily End-of-Year Insights:
- President Trump’s Vision for MFN Emerged in 2025, Shaped Global Policy
- EU HTA Regulation Moved From Design to Delivery in 2025
- Global Price Transparency in the MFN Era
- Decision-Makers Rushed to Embrace AI as They Weigh How to Use It Safely
- China Fine-tuned Policies to Champion Innovation
- ESG Requirements Became More Formalized in 2025
- Global M&A Expanded in Variety & Value, China Acted as Industry Bellwether
- NICE Policy & Decisions Roundup: H2, 2025
- Access to GLP-1s Expanded in 2025 With Key Launches, Coverage Decisions, & Major Policy Shifts
- Lenacapavir for HIV Prevention in LMICs: Learnings From 2025
As 2026 approaches, continuous intelligence remains essential in a landscape defined by ongoing change.
Download the 2025 Trends Newsletter.
Author Team
EVERSANA employs a team of over 6000 professionals across 20+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…